Roche’s Vabysmo Advantage Over Eylea Hard To See In Latest Head-To-Head

Both Drugs Dosed Monthly

 
• By Andrew McConaghie

Roche’s next-generation eye drug Vabysmo has enjoyed a strong launch, but new head-to-head trials in a potential new indication, retinal vein occlusion, appear to offers up few advantages over market leader Eylea.

Eye Test
Roche is aiming to add to Vabysmo's existing approvals in wet age-related macular degeneration and diabetic macular edema (DME). • Source: Shutterstock

More from Clinical Trials

More from R&D